drugset / Trial / NCT02485990
Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Phase 1
Terminated
24 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca · collabMedImmune LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will be looking at what dose of tremelimumab and olaparib is safe and effective in patients with persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma).
Timeline
- Start
- 2016-01-08
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
Outcome
Outcome not reported
Stopped: “Withdrawal of sponsor support”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 150 mg | Oral |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Tremelimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 10 mg/kg | Intravenous |